Bioniz is leveraging its unique expertise in cytokine biology to develop an entirely new class of human therapeutics targeting cytokines and their receptors. Bioniz platform technology allows custom design of its lead program to create novel peptides which selectively inhibit multiple cytokines without compromising the rest of the immune system. This innovative state-of -the- art drug development approach would enable Bioniz to address unmet medical needs in autoimmune diseases and cancer.